Brown & Brown, Inc.

Brown & Brown, Inc. Earnings Recaps

BRO Financials 2 recaps
Next earnings: January 25, 2027 (estimated) · full calendar
Q3 2026 Oct 28, 2026

Brown & Brown shares fell 5.0% after earnings, as investors likely focused on the 200-basis-point decline in adjusted EBITDAC margin and specialty distribution’s organic revenue decline, which came in below management’s expectations. Retail performed better than expected, but did not offset the weaker specialty result and modest overall organic growth.

Key takeaways
  • Revenue was $1.7 billion, up 7.4% year over year; organic revenue grew 1.2%, or 1.5% including organic contingents.
  • Adjusted EBITDAC margin fell 200 basis points to 34.6%; adjusted EPS increased nearly 2% to $1.07.
  • Retail organic revenue grew 2.6% (2.5% including contingents) and performed above the top end of expectations.
  • Specialty distribution organic revenue declined 0.8% (up 0.3% including contingents), below expectations; management cited increased competition from admitted carriers and movement of accounts out of the E&S market.
  • The company repurchased $750 million of shares through the first nine months, including $250 million in Q3, and raised its dividend 9% for the 33rd consecutive year.
Q3 2025 Oct 28, 2025

Brown & Brown, Inc. reported robust third-quarter results, with revenues growing 35.4% year-over-year and adjusted earnings per share increasing by 15% to $1.05. Strategic leadership appointments and a significant share repurchase program signal continued commitment to long-term growth and value creation.

Key takeaways
  • Revenues reached $1.6 billion, driven by strong organic growth of 3.5%, despite a challenging economic environment.
  • Adjusted EBITDAC margin improved by 170 basis points to 36.6%, highlighting operational efficiency.
  • The board approved a 10% dividend increase and expanded share repurchase authorization to $1.5 billion as part of its commitment to enhance shareholder value.
  • Seven acquisitions were completed, contributing an estimated $1.7 billion in annual revenues, underscoring the company's proactive growth strategy.
  • The company remains focused on addressing rising health care costs and maintaining competitive pricing in various insurance segments.